Outlook Therapeutics, Inc. Common Stock
OTLK
OTLK: Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
moreShow OTLK Financials
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of OTLK by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by OTLK's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
-
Patent Title: Buffer formulations for enhanced antibody stability Mar. 29, 2022
-
Patent Title: Modulation of charge variants in a monoclonal antibody composition Jun. 30, 2020
-
Patent Title: Buffer formulations for enhanced antibody stability Aug. 13, 2019
Government Contracts
Federal grants, loans, and purchases
Twitter
Followers on OTLK's company Twitter account
WallStreetBets
Number of mentions of OTLK in WallStreetBets Daily Discussion
OTLK News
Recent insights relating to OTLK
CNBC Recommendations
Recent picks made for OTLK stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in OTLK
Corporate Flights
Flights by private jets registered to OTLK